Pixium Vision SA represents a strong commitment to innovation and improving the lives of visually impaired individuals. The company focuses on developing innovative and breakthrough visual prosthetic systems, such as its flagship product, the Prima System. Pixium Vision SA aims to restore sight and enable greater independence for individuals with retinal dystrophies. With a patient-centered approach, the company emphasizes collaboration with healthcare professionals and strives to provide personalized solutions. Guided by a corporate philosophy rooted in research and development, Pixium Vision SA is dedicated to pushing the boundaries of vision restoration technology to enhance the quality of life for those affected by vision loss.

Pixium Vision SA is primarily present in France and Europe.

Pixium Vision SA has achieved several significant milestones. Firstly, the company successfully developed and launched its innovative retinal implant technology, the PRIMA System. This breakthrough product aims to restore vision for patients suffering from retinal dystrophies. In addition, Pixium Vision SA has made substantial progress in clinical trials, demonstrating the effectiveness and safety of their implants. The company has also obtained important regulatory approvals, including the European CE mark, further validating its cutting-edge technology. Furthermore, Pixium Vision SA has secured strategic partnerships, collaborations, and funding, enabling them to continue their research and development efforts. These achievements highlight Pixium Vision SA's commitment to advancing vision restoration and establishing itself as a leader in the field.

Pixium Vision SA is a leading company in the field of advanced retinal implants. Founded in 2011, Pixium Vision is dedicated to developing innovative solutions for patients suffering from vision loss. The company has a strong focus on research and development, working closely with leading experts in ophthalmology and vision science. Pixium Vision aims to provide cutting-edge technologies that restore partial vision to those affected by retinal degenerative diseases. With a commitment to improving the quality of life for visually impaired individuals, Pixium Vision continues to push the boundaries of retinal implant technology, making significant advancements in the field.

The main competitors of Pixium Vision SA in the market include companies like Second Sight Medical Products, Inc. and Retina Implant AG. These companies also specialize in developing and manufacturing innovative visual prostheses and implantable devices for the treatment of blindness or severe vision impairment. Pixium Vision SA competes with these companies in terms of technological advancements, product quality, market share, and research and development efforts. However, it is important to note that competition may vary depending on specific geographic regions and the niche markets that these companies target.

Pixium Vision SA is primarily active in the medical device industry, specifically in the field of ophthalmology. As a leading company in vision restoration, Pixium Vision specializes in developing innovative bionic vision systems. These systems aim to restore sight for individuals affected by retinal dystrophies or age-related macular degeneration. By harnessing advanced technology and expert knowledge, Pixium Vision is dedicated to providing cutting-edge solutions that improve the quality of life for visually impaired individuals. With a strong presence in the healthcare sector, Pixium Vision showcases its commitment to advancing ophthalmic care and enhancing visual perception.

Pixium Vision SA's business model centers around developing and commercializing innovative bionic vision systems. The company specializes in creating solutions for individuals with severe vision impairment or blindness. Pixium Vision SA's advanced technology focuses on designing retinal implants that stimulate the remaining functional cells and provide artificial vision to patients. By combining expertise in bioengineering, electronics, and artificial intelligence, the company aims to improve the quality of life for visually impaired individuals. With a strong commitment to research and development, Pixium Vision SA strives to revolutionize the field of vision restoration.

P/E-talet för Pixium Vision är −0,02.

Det Pixium Vision KUV är 0,45.

AlleAktien Qualitätsscore för Pixium Vision är 3/10.

förväntade Pixium Vision omsättningen är 824 000,00 EUR.

förväntade Pixium Vision vinst är −18,90 Mkr. EUR.

Pixium Vision SA is a French company founded in 2011. The company develops innovative eye implants that can be used to treat visual impairments and blindness. The business model of Pixium Vision SA is based on the development and manufacturing of implants that can restore or improve vision. The company works closely with leading scientists and medical institutions to constantly research and develop new technologies. Pixium Vision SA uses two technology platforms: the Prima platform and the Iris-II platform. The Prima platform is a miniaturized image processing technology that allows images to be projected onto the retina to treat visual impairments. The Iris-II platform, on the other hand, is a complete artificial retina that can be used as a replacement for natural vision. Overall, Pixium Vision SA offers two products: the Prima implant for the treatment of macular degeneration and the Iris-II implant for the treatment of retinitis pigmentosa. The Prima implant consists of a small, implantable device that is inserted into the eye and contains a microdisplay that can project images directly onto the retina. The Prima implant is currently being tested in a clinical study with patients with advanced dry age-related macular degeneration (dry-AMD). The Iris-II implant, on the other hand, is an artificial retina consisting of a matrix of electrically stimulable pixels. The device is used to treat retinitis pigmentosa, an inherited eye disease that can lead to vision loss. The Iris-II implant is currently in the development phase and clinical trials. In addition to developing implants, Pixium Vision SA also provides consulting services in the field of medical technology. The company works closely with doctors and medical institutions to ensure that the implants are properly implanted and used. The business model of Pixium Vision SA is based on the development and manufacturing of innovative eye implants that can treat visual impairments and blindness. The company relies on close collaboration with scientists and medical institutions to constantly research and develop new technologies. With its products, the Prima implant and the Iris-II implant, Pixium Vision SA offers patients worldwide innovative treatment options.

Pixium Vision delar ut en utdelning på 0 EUR fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för Pixium Vision eller så distribuerar bolaget inget utbyte.

ISIN för Pixium Vision är FR0011950641.

WKN för Pixium Vision är A116CC.

Ticker-symbolen för Pixium Vision är ALPIX.PA.

Under de senaste 12 månaderna betalade Pixium Vision en utdelning på . Detta motsvarar en direktavkastning på ungefär . För de kommande 12 månaderna förväntas Pixium Vision betala en utdelning på 0 EUR.

Aktiens direktavkastning för Pixium Vision är för närvarande .

Pixium Vision betalar ut dividenden kvartalsvis. Denna distribueras under månaderna .

Pixium Vision betalade utdelning varje år under de senaste 0 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 0 EUR. Detta motsvarar en utdelningsavkastning på 0 %.

Pixium Vision tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från Pixium Vision den 2024-09-11 på 0 EUR var du tvungen att ha aktien i ditt depå innan ex-dagen den 2024-09-11.

Utdelningen av den senaste dividenden skedde den 2024-09-11.

Under år 2023 delade Pixium Vision ut 0 EUR i form av utdelningar.

Utdelningarna från Pixium Vision betalas ut i EUR.